Veracyte reported new Phase III STAMPEDE data showing its Decipher Prostate Genomic Classifier predicted which very high-risk nonmetastatic prostate cancer patients benefited most from adding abiraterone to androgen deprivation therapy. Patients in higher-score groups saw a larger reduction in distant-metastasis risk. Decipher appears in National Comprehensive Cancer Network guidelines and is backed by real-world data from over 27,000 patients. That could raise testing volumes among physicians seeking clearer treatment guidance. Analysts expect revenue to grow about 11.9% a year, reaching $787.4 million by 2029. The consensus price target is $59.73, against a current share price of $46.04.

Insider selling: Veracyte (NASDAQ:VCYT) director sells 14,850 shares of company stock. October 28, 2026 Key points. * Veracyte director Karin Eastham sold 14,850 shares at an average price of $50, generating $742,500. The Rule 10b5-1 transaction reduced her direct holdings by 59.17% to 10,247 shares. * Veracyte shares were up 0.1% to $50.31, with a $4.04 billion market capitalization. The company recently exceeded quarterly earnings and revenue expectations, reporting $0.54 in EPS and $150.32 million in revenue. * Analyst sentiment remains a "Moderate Buy", with a consensus price target of $55.78, while institutional investors - including BlackRock, Dimensional Fund Advisors and First Trust Advisors - hold significant positions. * Interested in Veracyte? Here are five stocks we like better. Veracyte, Inc. (NASDAQ:VCYT - Get Free Report) Director Karin Eastham sold 14,850 shares of the stock in a transaction that occurred on Tuesday, October 27th. The shares were sold at an average price of $50.00, for a total value of $742,500.00. Following the transaction, the director directly owned 10,247 shares of the company's stock, valued at $512,350. The trade was a 59.17% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Veracyte stock up 0.1%. Shares of NASDAQ VCYT traded up $0.03 during midday trading on Wednesday, hitting $50.31. The stock had a trading volume of 1,397,792 shares, compared to its average volume of 1,143,253. The company has a market capitalization of $4.04 billion, a PE ratio of 35.68 and a beta of 1.95. The stock has a 50 day simple moving average of $43.86 and a 200-day simple moving average of $42.80. Veracyte, Inc. has a 1 year low of $29.45 and a 1 year high of $60.91. Veracyte (NASDAQ:VCYT - Get Free Report) last issued its earnings results on Thursday, July 30th. The biotechnology company reported $0.54 EPS for the quarter, beating analysts' consensus estimates of $0.41 by $0.13. The business had revenue of $150.32 million during the quarter, compared to analysts' expectations of $144.59 million. Veracyte had a net margin of 20.37% and a return on equity of 9.26%. The company's quarterly revenue was up 15.5% compared to the same quarter last year. During the same period in the prior year, the business earned $0.44 earnings per share. As a group, analysts expect that Veracyte, Inc. will post 1.32 earnings per share for the current fiscal year. Wall Street analysts forecast growth. A number of equities research analysts have recently issued reports on VCYT shares. Canaccord Genuity Group dropped their price target on Veracyte from $60.00 to $50.00 and set a "hold" rating for the company in a research report on Monday, August 3rd. Morgan Stanley reduced their price objective on Veracyte from $47.00 to $44.00 and set an "underweight" rating on the stock in a research report on Tuesday, August 4th. Weiss Ratings downgraded Veracyte from a "hold (c+)" rating to a "hold (c)" rating in a research report on Thursday, September 24th. UBS Group boosted their price objective on Veracyte from $52.00 to $65.00 and gave the stock a "buy" rating in a research note on Wednesday, September 9th. Finally, Wall Street Zen cut Veracyte from a "strong-buy" rating to a "buy" rating in a report on Saturday, October 10th. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $55.78. Discover more MarketBeat All Access MarketBeat Research Tools Hedge funds weigh in on Veracyte. Several institutional investors and hedge funds have recently bought and sold shares of VCYT. BlackRock Inc. acquired a new stake in shares of Veracyte during the 2nd quarter worth approximately $792,058,000. Dimensional Fund Advisors LP lifted its holdings in Veracyte by 2.9% in the first quarter. Dimensional Fund Advisors LP now owns 2,881,090 shares of the biotechnology company's stock valued at $92,787,000 after acquiring an additional 80,614 shares during the last quarter. First Trust Advisors LP lifted its holdings in Veracyte by 64.9% in the first quarter. First Trust Advisors LP now owns 2,117,046 shares of the biotechnology company's stock valued at $68,190,000 after acquiring an additional 833,543 shares during the last quarter. Congress Asset Management Co. purchased a new position in Veracyte in the third quarter worth approximately $89,971,000. Finally, Bank of America Corp DE grew its position in Veracyte by 14.7% in the first quarter. Bank of America Corp DE now owns 1,448,897 shares of the biotechnology company's stock worth $46,669,000 after acquiring an additional 185,929 shares during the period. About Veracyte. Veracyte, Inc is a diagnostics company that develops genomic tests to help physicians diagnose cancer, assess disease risk and guide treatment decisions. Its tests are designed to provide additional molecular information from patient samples, often helping reduce uncertainty and support more personalized care. The company's portfolio includes Afirma tests for thyroid nodules, Decipher tests for prostate cancer, Percepta tests for lung cancer and Envisio tests for breast cancer. Veracyte also develops and commercializes additional genomic assays intended for use across various cancer types and clinical settings. Founded in 2008 and headquartered in South San Francisco, California, Veracyte primarily serves the U.S. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Before you consider Veracyte, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Veracyte wasn't on the list. While Veracyte currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you'll find 7 stocks that could play a major role in the next tech-driven market boom. Continue following MarketBeat

Veracyte announces eight decipher-focused studies to be presented at ASTRO 2026. Six oral presentations and two posters will highlight Decipher's prognostic and predictive value in identifying patients' risk of progression and likelihood of benefiting from treatment intensification. September 25, 2026 17:12 ET | Source: Veracyte, Inc. SOUTH SAN FRANCISCO, Calif., Sept. 25, 2026 (GLOBE NEWSWIRE) - Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today that eight studies leveraging its Decipher Prostate Genomic Classifier test and whole-transcriptome data will be presented at the 2026 American Society for Radiation Oncology (ASTRO) Annual Meeting. The conference will take place September 26-30 in Boston. The presentations include analyses from Phase II and III clinical trials, Genomic Research for Intelligent Discovery (GRID) research, and national real-world studies. Together, they examine Decipher's prognostic value in assessing disease risk and predictive value in identifying which patients may benefit from treatment intensification, including adding androgen-deprivation therapy (ADT) to radiation. "The breadth of research being presented at ASTRO underscores the growing role of genomic information in helping clinicians navigate complex prostate cancer treatment decisions," said Elai Davicioni, Ph.D., Veracyte's medical director for Urology. "These presentations demonstrate how elucidating the molecular components of tumor biology may help personalize treatment decisions for patients across different stages of disease." The following Decipher-focused studies will be presented at ASTRO 2026: Oral Presentations Quick-Pitch Presentation * Title: Real-World Evidence across Prostate RT Modalities: Utilization Shifts, Toxicity and BCR in Genomic Classifier Scored Patients Presenter: Thomas Kole, M.D., Ph.D. Abstract: 1166 Date/Time: Tuesday, September 29, 5:35-5:40 p.m. ET Location: Room 205 Poster Presentations * Title: Preoperative Biopsy Decipher Prostate Genomic Classifier Predicts Earlier Secondary Radiotherapy After Radical Prostatectomy in National Real-World Data Presenter: Thomas Kole, M.D., Ph.D. Abstract: 3297 Date/Time: Sunday, September 27, 2:15-3:30 p.m. ET Location: Poster Hall, Exhibit Hall A * Title: Association of 22-Gene Genomic Classifier with ADT Use with Secondary Radiotherapy: A National Real-World Analysis Presenter: Andrew Barsky, M.D. Abstract: 3226 Date/Time: Tuesday, September 29, 2:15-3:30 p.m. ET Location: Poster Hall, Exhibit Hall A Additional information is available through the ASTRO 2026 Annual Meeting program. About Veracyte Veracyte (Nasdaq: VCYT) is a global diagnostics company with a vision to transform cancer care for patients around the world. The company's molecular tests assess the unique biology of each patient's tumor to help clinicians answer essential questions about cancer care. Veracyte's Diagnostics Platform combines broad genomic and clinical data, advanced bioinformatics and AI, and a powerful evidence-generation engine to support continued innovation and pipeline development. The company's portfolio includes the Afirma(R) Genomic Sequencing Classifier test, Decipher(R) Bladder Genomic Classifier test, Decipher(R) Prostate Genomic Classifier test, Prosigna(R) Breast Risk of Recurrence test, and the TrueMRD(TM) Monitoring Test for MIBC. For more information, visit Veracyte's website or follow the company on LinkedIn or X (Twitter). Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements, including but not limited to statements regarding the potential role of genomic information in helping identify which patients may benefit from treatment intensification and helping clinicians navigate prostate cancer treatment decisions and personalize treatment decisions for patients across different stages of disease. Forward-looking statements can be identified by words such as "anticipate," "believe," "expect," "may," "potential," "will," and similar expressions. Actual results may differ materially from those expressed or implied by these statements due to risks and uncertainties described under the caption "Risk Factors" in Veracyte's most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date of this release, and Veracyte disclaims any obligation to update them except as required by law. Veracyte, the Veracyte logo and Decipher are registered trademarks of Veracyte, Inc. and its subsidiaries in the United States and selected countries.